Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00366249




Registration number
NCT00366249
Ethics application status
Date submitted
17/08/2006
Date registered
21/08/2006
Date last updated
28/04/2010

Titles & IDs
Public title
Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.
Scientific title
A Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once-Daily Dose of Tigecycline Versus Ertapenem for the Treatment of Foot Infections in Subjects With Diabetes
Secondary ID [1] 0 0
3074K5-319
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Bacterial Infections 0 0
Diabetic Foot 0 0
Osteomyelitis 0 0
Condition category
Condition code
Infection 0 0 0 0
Studies of infection and infectious agents
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Sexually transmitted infections
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Tigecycline
Treatment: Drugs - Ertapenem

Active Comparator: A -

Active Comparator: B -


Treatment: Drugs: Tigecycline
150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis

Treatment: Drugs: Ertapenem
Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS) or enterococci coverage).
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Patients With Clinical Response of Cure Vs. Failure.
Timepoint [1] 0 0
Test of cure visit (TOC): Assessed at least 12 days post last dose
Primary outcome [2] 0 0
Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate.
Timepoint [2] 0 0
Test of cure visit (TOC): Assessed at least 12 days post last dose
Secondary outcome [1] 0 0
Number of Patients With Clinical Response of Cure Vs. Failure Assessed at Least 25 - 27 Weeks Post Last Dose.
Timepoint [1] 0 0
Test of cure visit (TOC): Assessed at least 25 - 27 weeks post last dose
Secondary outcome [2] 0 0
Number of Patients With Clinical Response of Cure Vs. Failure/Indeterminate Assessed at Least 25 - 27 Weeks Post Last Dose.
Timepoint [2] 0 0
Test of cure visit (TOC): Assessed at least 25 - 27 weeks post last dose
Secondary outcome [3] 0 0
Number of Patients With Microbiologic Response of Eradication.
Timepoint [3] 0 0
Test of cure visit (TOC): Assessed at least 12 days post last dose

Eligibility
Key inclusion criteria
Main inclusion criteria:

- Men and women aged 18 or older with diabetes and a qualifying foot infection. People
with evidence of a diabetic foot infection with osteomyelitis may qualify for the
osteomyelitis substudy arm.

Main exclusion criteria:

- People with additional significant disease, infection with resistant pathogens,
contraindication, or hypersensitivity to any test article or related antibiotic.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/01/2007
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/03/2009
Sample size
Target
Accrual to date
Final
1061
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
- Melbourne
Recruitment postcode(s) [1] 0 0
3050 - Melbourne
Recruitment postcode(s) [2] 0 0
3128 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Hawaii
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Maryland
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
New Jersey
Country [8] 0 0
United States of America
State/province [8] 0 0
North Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
Pennsylvania
Country [11] 0 0
United States of America
State/province [11] 0 0
South Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
Argentina
State/province [13] 0 0
Buenos Aires
Country [14] 0 0
Argentina
State/province [14] 0 0
Entre Rios
Country [15] 0 0
Argentina
State/province [15] 0 0
Entre Ríos
Country [16] 0 0
Argentina
State/province [16] 0 0
Mendoza
Country [17] 0 0
Argentina
State/province [17] 0 0
Provincia de Buenos Aires
Country [18] 0 0
Argentina
State/province [18] 0 0
Provincia de Tucuman
Country [19] 0 0
Argentina
State/province [19] 0 0
Santa Fe
Country [20] 0 0
Argentina
State/province [20] 0 0
Ciudad Autonoma de Buenos Aires
Country [21] 0 0
Argentina
State/province [21] 0 0
Cordoba
Country [22] 0 0
Austria
State/province [22] 0 0
Wien
Country [23] 0 0
Belgium
State/province [23] 0 0
Bornem
Country [24] 0 0
Belgium
State/province [24] 0 0
Brussel
Country [25] 0 0
Belgium
State/province [25] 0 0
Bruxelles
Country [26] 0 0
Belgium
State/province [26] 0 0
Pellenberg
Country [27] 0 0
Brazil
State/province [27] 0 0
Rio de Janeiro
Country [28] 0 0
Brazil
State/province [28] 0 0
Sao Paulo
Country [29] 0 0
Canada
State/province [29] 0 0
British Columbia
Country [30] 0 0
Canada
State/province [30] 0 0
Manitoba
Country [31] 0 0
Canada
State/province [31] 0 0
Ontario
Country [32] 0 0
Canada
State/province [32] 0 0
Quebec
Country [33] 0 0
Chile
State/province [33] 0 0
Santiago
Country [34] 0 0
Chile
State/province [34] 0 0
Valdivia
Country [35] 0 0
China
State/province [35] 0 0
Heilongjiang
Country [36] 0 0
China
State/province [36] 0 0
Beijing
Country [37] 0 0
China
State/province [37] 0 0
Guangzhou
Country [38] 0 0
China
State/province [38] 0 0
Tianjin
Country [39] 0 0
Colombia
State/province [39] 0 0
Bogota
Country [40] 0 0
Croatia
State/province [40] 0 0
Zadar
Country [41] 0 0
Croatia
State/province [41] 0 0
Zagreb
Country [42] 0 0
Denmark
State/province [42] 0 0
Odense
Country [43] 0 0
Estonia
State/province [43] 0 0
Ida Virumaa
Country [44] 0 0
Estonia
State/province [44] 0 0
Tallinn
Country [45] 0 0
Estonia
State/province [45] 0 0
Tartu
Country [46] 0 0
Finland
State/province [46] 0 0
Kuopio
Country [47] 0 0
Finland
State/province [47] 0 0
Turku
Country [48] 0 0
France
State/province [48] 0 0
Strasbourg
Country [49] 0 0
France
State/province [49] 0 0
Tourcoing
Country [50] 0 0
Germany
State/province [50] 0 0
Hessen
Country [51] 0 0
Germany
State/province [51] 0 0
North Rhine-Westphalia
Country [52] 0 0
Germany
State/province [52] 0 0
Northrhien-Westphalia
Country [53] 0 0
Greece
State/province [53] 0 0
Athens
Country [54] 0 0
Greece
State/province [54] 0 0
Holargos, Athens
Country [55] 0 0
Greece
State/province [55] 0 0
Rio-Patras
Country [56] 0 0
Hungary
State/province [56] 0 0
Budapest
Country [57] 0 0
Hungary
State/province [57] 0 0
Debrecen
Country [58] 0 0
Hungary
State/province [58] 0 0
Gyor
Country [59] 0 0
Hungary
State/province [59] 0 0
Kistarcsa
Country [60] 0 0
Hungary
State/province [60] 0 0
Szekesfehervar
Country [61] 0 0
India
State/province [61] 0 0
Gujarat
Country [62] 0 0
India
State/province [62] 0 0
Karnataka
Country [63] 0 0
India
State/province [63] 0 0
Maharashtra
Country [64] 0 0
India
State/province [64] 0 0
Rajasthan
Country [65] 0 0
Italy
State/province [65] 0 0
Abano terme (PD)
Country [66] 0 0
Italy
State/province [66] 0 0
Pisa
Country [67] 0 0
Italy
State/province [67] 0 0
Rome
Country [68] 0 0
Korea, Republic of
State/province [68] 0 0
Gyeonggi-do
Country [69] 0 0
Korea, Republic of
State/province [69] 0 0
Seoul
Country [70] 0 0
Latvia
State/province [70] 0 0
Liepaja
Country [71] 0 0
Latvia
State/province [71] 0 0
Riga
Country [72] 0 0
Lithuania
State/province [72] 0 0
Kaunas
Country [73] 0 0
Lithuania
State/province [73] 0 0
Klaipeda
Country [74] 0 0
Lithuania
State/province [74] 0 0
Panevezys
Country [75] 0 0
Lithuania
State/province [75] 0 0
Siauliai
Country [76] 0 0
Lithuania
State/province [76] 0 0
Vilnius
Country [77] 0 0
Mexico
State/province [77] 0 0
Guadalajara
Country [78] 0 0
Mexico
State/province [78] 0 0
Jalisco
Country [79] 0 0
Mexico
State/province [79] 0 0
Sonora
Country [80] 0 0
Mexico
State/province [80] 0 0
Durango
Country [81] 0 0
Mexico
State/province [81] 0 0
Mendoza
Country [82] 0 0
Mexico
State/province [82] 0 0
San Luis Potosi
Country [83] 0 0
Mexico
State/province [83] 0 0
Santa Fe
Country [84] 0 0
Mexico
State/province [84] 0 0
Veracruz
Country [85] 0 0
Panama
State/province [85] 0 0
Panama
Country [86] 0 0
Peru
State/province [86] 0 0
Lima
Country [87] 0 0
Poland
State/province [87] 0 0
Bielsko-Biala
Country [88] 0 0
Poland
State/province [88] 0 0
Cieszyn
Country [89] 0 0
Poland
State/province [89] 0 0
Gdansk
Country [90] 0 0
Poland
State/province [90] 0 0
Lodz
Country [91] 0 0
Poland
State/province [91] 0 0
Warsaw
Country [92] 0 0
Poland
State/province [92] 0 0
Wroclaw
Country [93] 0 0
Portugal
State/province [93] 0 0
Lisboa
Country [94] 0 0
Portugal
State/province [94] 0 0
Lisbon
Country [95] 0 0
Romania
State/province [95] 0 0
Bacau
Country [96] 0 0
Romania
State/province [96] 0 0
Bucharest
Country [97] 0 0
Romania
State/province [97] 0 0
Cluj-Napoca
Country [98] 0 0
Romania
State/province [98] 0 0
Lasi
Country [99] 0 0
Russian Federation
State/province [99] 0 0
Chelyabinsk
Country [100] 0 0
Russian Federation
State/province [100] 0 0
Ekaterinburg
Country [101] 0 0
Russian Federation
State/province [101] 0 0
Kemerovo
Country [102] 0 0
Russian Federation
State/province [102] 0 0
Moscow
Country [103] 0 0
Russian Federation
State/province [103] 0 0
Nizhniy Novgorod
Country [104] 0 0
Russian Federation
State/province [104] 0 0
Nizhny Novgorod
Country [105] 0 0
Russian Federation
State/province [105] 0 0
Novosibirsk
Country [106] 0 0
Russian Federation
State/province [106] 0 0
Omsk
Country [107] 0 0
Russian Federation
State/province [107] 0 0
Smolensk
Country [108] 0 0
Russian Federation
State/province [108] 0 0
St. Petersburg
Country [109] 0 0
Russian Federation
State/province [109] 0 0
Yaroslavl
Country [110] 0 0
Slovakia
State/province [110] 0 0
Banska Bystrica
Country [111] 0 0
Slovakia
State/province [111] 0 0
Banska.Bysterica
Country [112] 0 0
Slovakia
State/province [112] 0 0
Bratislava
Country [113] 0 0
Slovakia
State/province [113] 0 0
Lubochna
Country [114] 0 0
Slovakia
State/province [114] 0 0
Martin
Country [115] 0 0
Slovakia
State/province [115] 0 0
Nitra
Country [116] 0 0
Slovakia
State/province [116] 0 0
Nove Zamky
Country [117] 0 0
South Africa
State/province [117] 0 0
Eastern Cape
Country [118] 0 0
South Africa
State/province [118] 0 0
Gauteng
Country [119] 0 0
Spain
State/province [119] 0 0
Barcelona
Country [120] 0 0
Spain
State/province [120] 0 0
Getafe Madrid
Country [121] 0 0
Spain
State/province [121] 0 0
Granada
Country [122] 0 0
Spain
State/province [122] 0 0
Madrid
Country [123] 0 0
Spain
State/province [123] 0 0
Palma de Mallorca
Country [124] 0 0
Sweden
State/province [124] 0 0
Copenhagen
Country [125] 0 0
Sweden
State/province [125] 0 0
Huddinge
Country [126] 0 0
Sweden
State/province [126] 0 0
Uppsala
Country [127] 0 0
Switzerland
State/province [127] 0 0
Basel
Country [128] 0 0
Switzerland
State/province [128] 0 0
Geneva
Country [129] 0 0
Taiwan
State/province [129] 0 0
Tainan
Country [130] 0 0
Taiwan
State/province [130] 0 0
Taoyuan Hsien
Country [131] 0 0
Turkey
State/province [131] 0 0
Adana
Country [132] 0 0
Turkey
State/province [132] 0 0
Capa-Istanbul
Country [133] 0 0
Turkey
State/province [133] 0 0
Istanbul
Country [134] 0 0
Ukraine
State/province [134] 0 0
Cherkassy
Country [135] 0 0
Ukraine
State/province [135] 0 0
Dnepropetrovsk
Country [136] 0 0
Ukraine
State/province [136] 0 0
Kiev
Country [137] 0 0
Ukraine
State/province [137] 0 0
Kyiv
Country [138] 0 0
Ukraine
State/province [138] 0 0
Lviv
Country [139] 0 0
Ukraine
State/province [139] 0 0
Vinnytsia
Country [140] 0 0
Ukraine
State/province [140] 0 0
Zaporozhye
Country [141] 0 0
United Kingdom
State/province [141] 0 0
Lanarkshire
Country [142] 0 0
United Kingdom
State/province [142] 0 0
West Midlands
Country [143] 0 0
United Kingdom
State/province [143] 0 0
Birmingham
Country [144] 0 0
United Kingdom
State/province [144] 0 0
London
Country [145] 0 0
United Kingdom
State/province [145] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Wyeth is now a wholly owned subsidiary of Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study was to look at the safety and effectiveness of a once-daily dose of
tigecycline compared to ertapenem for the treatment of diabetic foot infections. The
co-primary efficacy endpoints were not met.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00366249
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Monitor
Address 0 0
Wyeth is now a wholly owned subsidiary of Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00366249